期刊文献+

利用循证方法对1例应用新型靶向药患者的药学服务

Pharmaceutical care for a patient using a new targeted drug by evidence-based method
下载PDF
导出
摘要 全球范围内,卵巢癌已占据女性常见恶性肿瘤第6位,死亡率居妇科肿瘤中死亡之首[1]。超过70%患者发现时已是高级阶段,需要化疗。尽管化疗给药方案不断改进,每年仍约有14000人死亡[1,2]。自1996年以来,一线的标准方案卡铂+紫杉类,一直是手术治疗后标注治疗方案[3]。不幸的是,尽管最初反应率高,大多数患者复发后需要额外的治疗方案。
作者 范瑞 黄莹 刘飞 FAN Rui;HUANG Ying;LIU Fei
出处 《新疆医学》 2020年第10期1106-1108,共3页 Xinjiang Medical Journal
  • 相关文献

参考文献4

二级参考文献46

  • 1林仲秋,杨清元.卵巢癌复发的相关因素[J].中国实用妇科与产科杂志,2005,21(7):386-387. 被引量:2
  • 2易晓芳,丰有吉.复发性卵巢癌的化疗进展[J].肿瘤学杂志,2006,12(2):99-102. 被引量:9
  • 3Ingo G.H. Schmidt-Wolf,Petja Lefterova,Valerie Johnston,Christian Scheffold,Markus Csipai,Bela A. Mehta,Takashi Tsuruo,Dieter Huhn,Robert S. Negrin.Sensitivity of Multidrug-Resistant Tumor Cell Lines to Immunologic Effector Cells[J].Cellular Immunology.1996(1)
  • 4Shawna L. Bull Phelps,John O. Schorge,Michael J. Peyton,Hisayuki Shigematsu,Li-Lin Xiang,David S. Miller,Jayanthi S. Lea.Implications of EGFR inhibition in ovarian cancer cell proliferation[J].Gynecologic Oncology.2008(3)
  • 5Domchek SM,Weber BL.Clinical management of BRCA1 and BRCA2 mutation carriers[J].Oncogene,2006,25(43):5 825-5 831.
  • 6Frampton JE.Olaparib:a review of its use as maintenance therapy in patients with ovarian cancer[J].Bio Drugs,2015,29(2):143-150.
  • 7Kaye SB,Lubinski J,Matulonis U,et al.PhaseⅡ,open-label,randomized,multicenter study comparing the efficacy and safety of olaparib,a poly(ADP-ribose)polymerase inhibitor,and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer[J].J Clin Oncol,2012,30(4):372-379.
  • 8Ledermann J,Harter P,Gourley C,et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer:a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial[J].Lancet Oncol,2014,15(8):852-861.
  • 9Oza AM,Cibula D,Benzaquen AO,et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer:a randomised phase 2 trial[J].Lancet Oncol,2015,16(1):87-97.
  • 10Audeh MW,Carmichael J,Penson RT,et al.Oral poly(ADP-ribose)polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer:a proof-of-concept trial[J].Lancet,2010,376(9 737):245-251.

共引文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部